Physician profile
Haley Dawn Harrelson
NPI 1578988168
$3,838.74
in general payments reported to CMS, 2019-2025
27 companies · $327 in 2025
The $327 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $689 · 2022: $1,586 · 2023: $801 · 2024: $436 · 2025: $327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,564.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,564.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $948.96 | 2021-2025 | Corevalve Evolut R, Hawkone, Abre |
| Boston Scientific Corporation | $417.43 | 2021-2025 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Astrazeneca Pharmaceuticals LP | $361.52 | 2021-2023 | Farxiga |
| Novartis Pharmaceuticals Corporation | $276.72 | 2021-2025 | |
| Glaxosmithkline, LLC. | $276.69 | 2022-2023 | Trelegy Ellipta |
| Inari Medical, INC. | $199.01 | 2022-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Genzyme Corporation | $195.49 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $154.81 | 2022-2023 | Dupixent |
| Stryker Corporation | $120.92 | 2021-2025 | Target, Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Astellas Pharma US INC | $118.03 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $98.26 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $97.41 | 2022-2023 | Cuvitru |
| Amgen INC. | $89.10 | 2022-2023 | Repatha, Tezspire |
| Abiomed | $65.14 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $59.99 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $55.07 | 2022 | |
| Mylan Specialty L.P. | $51.48 | 2022 | |
| Merck Sharp & Dohme LLC | $50.72 | 2021-2023 | Verquvo |
| Abbott Laboratories | $42.82 | 2021-2023 | Gallant |
| Angiodynamics, INC. | $35.12 | 2022-2023 | Alphavac |
| Lexicon Pharmaceuticals, INC. | $25.03 | 2023 | Inpefa |
| Grifols USA, LLC | $20.82 | 2023 | Xembify |
| Genentech USA, INC. | $18.11 | 2022 | |
| Pfizer INC. | $16.93 | 2022 | |
| Janssen Pharmaceuticals, INC | $15.98 | 2022 | |
| Pharming Healthcare, INC. | $14.54 | 2022 | |
| Abbvie INC. | $12.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haley Harrelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.